Commentary|Articles|November 16, 2026

Dr Cortes on the Rationale Behind the OPTIC Trial in CML

Fact checked by: Riley Kandel
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.

Jorge Cortes, MD, explains how lowering the ponatinib dose after response reduced arterial occlusive risk in resistant chronic myeloid leukemia.

"By decreasing the dose once the patient achieves a response, we could significantly decrease the risk of these arterial occlusive events. Whereas in the past we had a risk of 25% to 35%, this went down to 15%."

Jorge Cortes, MD, chief of hematology in the Division of Hematology and Oncology and deputy director of the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, discussed 5-year follow-up data from the phase 2 OPTIC trial (NCT02467270) evaluating response-based dosing of ponatinib (Iclusig) in patients with chronic-phase chronic myeloid leukemia (CML) resistant to at least 2 prior TKIs or harboring a BCR::ABL1 T315I mutation.

Want more insights about the OPTIC trial, its data, and ponatinib? Be sure to check out our conversation with Hagop M. Kantarjian, MD, on the topic.

Ponatinib is highly effective and was the first agent with activity against BCR::ABL1 T315I mutations, Cortes explained. However, an unexpected, high risk of arterial occlusive events later emerged, he said. OPTIC tested whether lower starting doses, or dose reduction after response, could reduce that risk while maintaining efficacy, he added.

In the trial, patients were randomly assigned to starting doses of 45 mg (n = 94), 30 mg (n = 95), or 15 mg (n = 94) daily, with the 45- and 30-mg arms reduced to 15 mg upon achieving BCR::ABL1 responses of 1% or less. Twelve-month BCR::ABL1 responses were met by 60%, 41%, and 40% of patients in each dosing group respectively.

According to Cortes, the data confirmed 45 mg as the optimal starting dose, consistent with previous studies. The magnitude of benefit depended on mutation status, he noted; among patients with BCR::ABL1 T315I mutations, 64%, 25%, and 16% achieved the primary end point across the 45-, 30-, and 15-mg arms, respectively, vs 56%, 40%, and 50% among those with mutations other than T315I. Most patients maintained response after dose reduction; more patients with T315I lost response, but most regained it after re-escalation, Cortes said.

Exposure-adjusted arterial occlusive events rates were similar between 45 mg and 30 mg doses of ponatinib, Cortes said, noting that the 30 mg dose may potentially compromise efficacy without significantly improving safety. Starting at 45 mg and reducing to 15 mg once a patient responds is now the approved dosing on the ponatinib label, and it is how he recommends using the agent, Cortes concluded.


Related to this article